Ground-level proof points accumulating: management narrates several small, named, recent wins and treats them as the lea
The model's full reasoning — Q2 2023 call → NOWe need to answer YES or NO based on the criteria. The question asks: does management's account rest on several small, concrete, ground-level wins that it names and describes individually, and does management explicitly treat these accumulating episodes as the leading edge of a broader improvement still early? We need to check the transcript for at least three distinct, named or individually identifiable episodes from the recent period, described specifically enough. And management must connect them into a building pattern that is still early. Let's review the transcript. Management (Laurent Levy and Bart Van Rhijn) discuss: - The global license agreement with Janssen, which is a major deal. That's a big event, not necessarily a small ground-level win? But it's a specific event. However, the question asks for "several small, concrete, ground-level wins" - like particular customers, sites, products, etc. The Janssen deal is a big partnership, but it's a single event. Also, they mention the appointment of Dr. Kayitalire as CMO. That's a personnel change, not a ground-level win. - They mention "In July, the first patient was injected in the newest MDLA (ph) study, a Phase 1/2 study evaluating radiotherapy activated in combination with an anti-PD-1/PD-L1 in a checkpoint inhibitor in patients with advanced solid tumor with lung or liver metastasis." That's a specific event: first patient injected in a new study. That's a concrete episode. - They mention "MD Anderson has made significant progress in its Phase 1 trial of NBTXR3 in operable non-small cell lung cancer and expect to determine a recommended Phase 2 dose for this product in the second half of this year." That's progress, but not a specific completed event? It says "significant progress" and expects to determine RP2D later. That's not a concrete episode that happened. - They mention "we expect to present safety and efficacy data at a medical meeting in the coming weeks" for Study 102. That's future. - They mention "we anticipate providing a Phase 1 data update between now and the first half of 2024" for IO combination. - They mention "the first patient was injected" - that's one episode. - They also mention "the company already received the $30 million upfront cash licensing fee" and "the first equity charge of $5 million" - those are financial events, but they are part of the Janssen deal.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| TGI | Triumph Group, Inc. | Q2 2017 | 2016-11-03 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
AU · Q2 2018 → YESThe question is: Does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from insid...YES The transcript shows multiple specific, recent operational episodes: Kibali’s underground ramp-up with automated ore handling system and vertical shaft integration; Iduapriem’s CIL tank conversion and grade/tonnage gains; Sunrise Dam’s Recovery Enhancement Project plus new mining strategies; Tropicana’s second 6-MW ball mill installation; Siguiri’s CIL circuit milestone; and 338 tracked Operational Excellence projects.
BXP · Q1 2022 → YESThe question is: Does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from insid...YES The transcript shows multiple distinct, named episodes from the recent period: the 73,000 sq ft recapture/release at 77 CityPoint with a 15% rent increase and 7.
CRGO · Q1 2024 → YESThe question is: Does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from insid...